BUB
ICPT

BBVA USA Bancshares’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

BBVA USA Bancshares’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,112
Closed -$348K – 574
2016
Q3 		$348K Buy
2,112
+164
+8% +$25.9K 0.03% 425
2016
Q2 		$278K Buy
1,948
+99
+5% +$14.4K 0.02% 452
2016
Q1 		$238K Buy
+1,849
New +$218K 0.02% 472

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

BBVA USA Bancshares's ICPT Position: Q4 2016 in Review

BBVA USA Bancshares sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2016, closing a stake of 2,112 shares — an estimated $348K sold.

BBVA USA Bancshares first reported a position in ICPT in Q1 2016 and held it in 3 quarters. The position peaked at $348K in Q3 2016. 159 funds tracked by Wall St. Rank hold ICPT as of Q4 2016.

  • BBVA USA Bancshares reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • BBVA USA Bancshares sold 2,112 Intercept Pharmaceuticals, Inc. shares in Q4 2016, an estimated $348K.
  • BBVA USA Bancshares first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
  • BBVA USA Bancshares's Intercept Pharmaceuticals, Inc. position peaked at $348K in Q3 2016.
  • 159 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2016.

Based on BBVA USA Bancshares's 13F filing for Q4 2016, filed 8 Feb 2017.